Plerixafor Injection
Plerixafor Injection is a stem cell mobilizer given with filgrastim to help collect stem cells from the blood for a later autologous transplant in people with non-Hodgkin's lymphoma or multiple myeloma.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 13 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
How we combine label and product data →
Plerixafor (Mozobil), on the market since about 2013 and available generically, is a specialist drug given with filgrastim to move stem cells from the bone marrow for collection before an autologous transplant (your own cells given back later) in non-Hodgkin's lymphoma or multiple myeloma; it blocks the CXCR4 receptor and its anchoring signal, SDF-1α. Most people handle the short course well; diarrhea, nausea and injection site redness or soreness are the usual complaints. Watch for any allergic symptoms (you are observed for at least 30 minutes after each dose), and report left upper belly or shoulder pain right away, since it can mean an enlarged or ruptured spleen.
Clinical pearls
- It starts after four days of filgrastim and is timed about 11 hours before each day's collection.
- Your kidneys matter here, since the dose is figured from body weight and lowered when kidney function is reduced.
- Expect blood tests during mobilization, because plerixafor can lower platelets and push white blood cell counts very high.
- Women who could become pregnant, and men, should use effective contraception through one week after the last dose.
Patient information guide — a plain-language walkthrough of Plerixafor Injection, written from its FDA label.
What Plerixafor Injection is used for
▾
Plerixafor Injection is used together with filgrastim to mobilize stem cells for collection.
- Collecting blood-forming stem cells for a later autologous transplant in people with non-Hodgkin's lymphoma
- Collecting blood-forming stem cells for a later autologous transplant in people with multiple myeloma
How Plerixafor Injection works
▾
Plerixafor blocks the CXCR4 receptor and the signal (SDF-1α) that helps anchor stem cells in the bone marrow. When that anchor is blocked, more stem cells move into the bloodstream. They can then be collected for transplant.
Stem cells mobilized this way were able to engraft in animal transplant studies.
Plerixafor Injection dosage
▾
Plerixafor Injection is given under the skin by a healthcare team. It is started after 4 days of daily filgrastim, and given about 11 hours before each collection session for up to 4 days in a row.
- The dose depends on your body weight.
- The dose is lowered if your kidney function is reduced.
- Food is not part of the label's instructions.
Follow your prescriber and the product label.
Dosing details from the FDA-approved label
From the Plerixafor Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Patients weighing less than or equal to 83 kg (creatinine clearance greater than 50 mL/min)
- 20 mg fixed dose or 0.24 mg/kg of body weight by subcutaneous injection once daily, approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days
- Begin after the patient has received filgrastim once daily for 4 days
- Use actual body weight; dose of 20 mg or 0.24 mg/kg
- Patients weighing greater than 83 kg (creatinine clearance greater than 50 mL/min)
- 0.24 mg/kg of body weight by subcutaneous injection once daily, approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days
- Begin after the patient has received filgrastim once daily for 4 days
- Maximum: 40 mg/day
- Use actual body weight; patients weighing more than 175% of ideal body weight not investigated
- Renal impairment (creatinine clearance less than or equal to 50 mL/min), body weight less than or equal to 83 kg
- 13 mg or 0.16 mg/kg once daily
- Dose reduced by one-third; insufficient information for patients on hemodialysis
- Renal impairment (creatinine clearance less than or equal to 50 mL/min), body weight greater than 83 kg and less than 160 kg
- 0.16 mg/kg once daily
- Maximum: 27 mg/day
- Dose reduced by one-third; insufficient information for patients on hemodialysis
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Initiate Plerixafor Injection treatment after the patient has received filgrastim once daily for 4 days. ( 2.1 ) Repeat Plerixafor Injection dose up to 4 consecutive days. ( 2.1 ) Dose based on patient weight Less than or equal to 83 kg: 20 mg dose or select dose based on 0.24 mg/kg actual body weight. ( 2.1 ) Greater than 83 kg: select dose based on 0.24 mg/kg actual body weight. ( 2.1 ) Administer by subcutaneous injection approximately 11 hours prior to initiation of apheresis. ( 2.1 ) Renal impairment: If creatinine clearance is ≤50 mL/min, decrease dose by one-third to 0.16 mg/kg. ( 2.3 ) 2.1 Recommended Dosage and Administration Begin treatment with Plerixafor Injection after the patient has received filgrastim once daily for 4 days [see Dosage and Administration ( 2.2 )]. Administer Plerixafor Injection approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days. The recommended dose of Plerixafor Injection by subcutaneous injection is based on body weight: 20 mg fixed dose or 0.24 mg/kg of body weight for patients weighing less than or equal to 83 kg. [see Clinical Pharmacology ( 12.3 )] 0.24 mg/kg of body weight for patients weighing greater than 83 kg Use the patient's actual body weight to calculate the volume of Plerixafor Injection to be administered. Each vial delivers 1.2 mL of 20 mg per mL solution, and the volume to be administered to patients should be calculated from the following equation: 0.012 × patient's actual body weight (in kg) = volume to be administered (in mL) In clinical studies, Plerixafor Injection dose has been calculated based on actual body weight in patients up to 175% of ideal body weight. Plerixafor Injection dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated. Based on increasing exposure with increasing body weight, the Plerixafor Injection dose should not exceed 40 mg/day [see Clinical Pharmacology ( 12.3 )]. Vials should be inspected visually for particulate matter and discoloration prior to administration and should not be used if there is particulate matter or if the solution is discolored. Discard unused portion.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Plerixafor Injection side effects
▾
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Injection site reactions (redness, pain, itching, swelling)
- Headache
- Joint pain (arthralgia)
- Dizziness
When to get medical help
- Signs of a serious allergic reaction, such as hives, swelling around the eyes, trouble breathing, or very low blood pressure. These can happen within about 30 minutes.
- Pain in the left upper abdomen or near the shoulder or shoulder blade, which can signal an enlarged or ruptured spleen.
- Fainting, lightheadedness when standing, or feeling faint after the injection.
- Low platelet counts or very high white blood cell counts, which your team will monitor with blood tests.
The most common side effects (10% or more of people) were:
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Injection site reactions
- Headache
- Joint pain
- Dizziness
Seek medical help for allergic symptoms, fainting, or pain in the left upper abdomen or shoulder area.
Plerixafor Injection warnings and precautions
▾
- Serious allergic reactions, including anaphylactic shock, have occurred. You are watched for at least 30 minutes after each dose.
- Leukemia: it should not be used for stem cell collection in people with leukemia.
- Blood counts: white blood cells can rise and platelets can fall, so counts are monitored.
- Tumor cells may be released from the marrow and collected. The effect of reinfusing them is unknown.
- Spleen: enlargement and rupture have been reported.
- Pregnancy: it can cause fetal harm.
Before taking Plerixafor Injection
▾
- Do not use it if you have had an allergic reaction to plerixafor.
- Tell your doctor about kidney problems, since the dose is reduced.
- Pregnancy status should be checked first. Use effective contraception during treatment and for one week after the last dose.
- Breastfeeding is not recommended during treatment and for one week after.
- Safety and effectiveness are not established in children.
- It is not intended for people with leukemia.
Plerixafor Injection overdose
▾
At doses above the recommended amount, stomach and bowel problems, vasovagal reactions (fainting-type reactions), low blood pressure on standing, and fainting may be more frequent. Data are limited.
What Plerixafor Injection does in the body
▾
Plerixafor raises the number of stem cells (CD34+ cells) in the blood. In two placebo-controlled studies, the increase was about 5-fold with plerixafor plus filgrastim, compared with about 1.4 to 1.7-fold with placebo plus filgrastim. In healthy volunteers, the peak effect came roughly 6 to 14 hours after a dose. It did not show an effect on heart rhythm (QT interval) at single doses studied.
How your body processes Plerixafor Injection
▾
After an injection under the skin, blood levels peak in about 30 to 60 minutes. Plerixafor is not broken down by the liver and has a low potential for interactions through liver enzymes. It is cleared mainly through the urine, with about 70% leaving unchanged in 24 hours. The half-life is roughly 3 to 5 hours. Reduced kidney function raises drug levels, so the dose is lowered.
How to store Plerixafor Injection
▾
Store at 20º to 25ºC (68º to 77ºF).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Plerixafor Injection: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Plerixafor Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is this medicine for?
▾
How and when will I get it?
▾
What side effects should I expect?
▾
What should I tell the team right away?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Do my kidneys matter?
▾
Is Plerixafor Injection available over the counter?
▾
When was Plerixafor Injection first available?
▾
Who makes Plerixafor Injection?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Plerixafor Injection on HelloPharmacist
Plerixafor Injection forms and strengths (how it comes)
Plerixafor Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Plerixafor Injection is used with filgrastim to mobilize stem cells for collection before an autologous transplant in non-Hodgkin's lymphoma or multiple myeloma.
- Plerixafor Injection is given by subcutaneous injection about 11 hours before each apheresis, for up to 4 days in a row.
- Plerixafor Injection is started after 4 days of daily filgrastim.
- Plerixafor Injection dosing is based on body weight and is reduced for lower kidney function.
Plerixafor Injection on the U.S. market: products, makers and brands
How Plerixafor Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
15 companies list 24 Plerixafor Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2008. Brand names on the directory include Mozobil; the rest are generics.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Plerixafor Injection is used (Medicaid data)
A general measure of how commonly Plerixafor Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Plerixafor Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Plerixafor Injection prescribed? Of the 1,601 medications we measure, Plerixafor Injection ranks #1,551 by Medicaid prescriptions — more than 3% of them.
Utilization by Plerixafor Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
1.2 ML plerixafor 20 MG/ML Injection
Summed across the 1 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 828700
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Plerixafor Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 14 listed Plerixafor Injection NDCs with Medicaid activity.
Compare Plerixafor Injection products
A representative set of FDA-listed product records for Plerixafor Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 24 mg/1.2 mL | Subcutaneous | Amneal Pharmaceuticals LLC × 2 listings | ANDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Bryant Ranch Prepack | ANDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Dr. Reddy's Laboratories Inc × 2 listings | ANDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Eugia US LLC × 2 listings | ANDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Fresenius Kabi Usa, LLC × 2 listings | NDA AUTHORIZED GENERIC | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Gland Pharma Limited | ANDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Meitheal Pharmaceuticals Inc. × 2 listings | ANDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Novadoz Pharmaceuticals LLC × 2 listings | ANDA | View NDC → |
| 24 mg/1.2 mL | — | Patheon Manufacturing Services LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 20 mg/mL | Subcutaneous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Sanofi-Aventis U.S. LLC × 3 listings | NDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Teva Pharmaceuticals, Inc. | ANDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Zydus Lifesciences Limited | ANDA | View NDC → |
| 24 mg/1.2 mL | Subcutaneous | Zydus Pharmaceuticals USA Inc. × 2 listings | ANDA | View NDC → |
Showing 24 of 24 products — FDA National Drug Code Directory. See every product, package size and price: browse all 24 Plerixafor Injection NDCs →
Plerixafor Injection side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Plerixafor Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Plerixafor Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Plerixafor Injection FDA approval history
How Plerixafor Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Plerixafor Injection recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Plerixafor recalls since July 2021.
✅No Plerixafor recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 733003 1 dose form · 1 strength
-
Dose form (SCDF) Injection RxCUI 1794537In current FDA listingsClinical drug / strength (SCD) 1.2 ML plerixafor 20 MG/MLRxCUI 828700
Look up RxCUI 733003 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Plerixafor Injection supply and shortage status
Whether Plerixafor Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Plerixafor Injection brand names
Plerixafor Injection is sold under one brand name in the FDA directory — Mozobil. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Plerixafor Injection: manufacturers and labelers
15 companies list Plerixafor Injection products with the FDA. By number of product records, the largest are sanofi-aventis U.S. LLC, Amneal Pharmaceuticals LLC, Dr. Reddy's Laboratories Inc. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Plerixafor Injection drug class (RxNorm)
Plerixafor Injection belongs to the Hematopoietic Stem Cell Mobilizer class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Plerixafor Injection page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Fresenius Kabi Usa, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →